Hikma Pharmaceuticals Plc Notice of Results
15 Julho 2024 - 3:00AM
RNS Regulatory News
RNS Number : 2908W
Hikma Pharmaceuticals Plc
15 July 2024
London, 15 July 2024
- Hikma Pharmaceuticals
PLC (Hikma, Group), will announce its interim financial results for
the six months ended 30 June 2024 on Thursday 8 August
2024.
A recording of the presentation will
be available on the Group's website at www.hikma.com
from 7:00am BST. Hikma will also hold a live
Q&A conference call for analysts at 9:30am BST, and a recording
will be made available on the Company's website.
To join via conference call please
dial:
United Kingdom (Local): +44 20 3936
2999
United Kingdom (Toll-Free): +44 800
358 1035
Global
Dial-In Numbers
Access Code: 229737
- ENDS
-
Enquiries
Hikma Pharmaceuticals
PLC
Susan Ringdal
EVP, Strategic Planning and Global
Affairs
|
+44 (0)20 7399 2760/ +44 (0)7776
477050
|
Guy Featherstone
Director, Investor
Relations
|
+44 (0)20 3892 4389/ +44 (0)7795
896738
|
Layan Kalisse
Senior Associate, Investor Relations
|
+44 (0)20 7399 2788/ +44 (0)7970
709912
|
Teneo (Press)
Doug Campbell / Rob Yates
|
+44 (0)7753 136628/ +44 (0)7715
375443
|
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated
BBB-/stable S&P and BBB-/positive Fitch)
Hikma helps put better health within
reach every day for millions of people around the world. For more
than 45 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit:
www.hikma.com
©2024 Hikma Pharmaceuticals PLC. All
rights reserved.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORMZGMNKZFGDZM
Hikma Pharmaceuticals (LSE:HIK)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Hikma Pharmaceuticals (LSE:HIK)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024